**Publications**

1. Takiff HE, Reinhold W, Garon CF, Straus SE. Cloning and physical mapping of enteric adenoviruses (candidate types 40 and 41). J Virol. 1984;51(1):131-6. PubMed PMID: 6328032.

2. Straus SE, Reinhold W, Smith HA, Ruyechan WT, Henderson DK, Blaese RM, et al. Endonuclease analysis of viral DNA from varicella and subsequent zoster infections in the same patient. N Engl J Med. 1984;311(21):1362-4. PubMed PMID: 6092956.

3. Ruyechan WT, Casey TA, Reinhold W, Weir AC, Wellman M, Straus SE, et al. Distribution of G + C-rich regions in varicella-zoster virus DNA. J Gen Virol. 1985;66(Pt 1):43-54. PubMed PMID: 2981960.

4. Casey TA, Ruyechan WT, Flora MN, Reinhold W, Straus SE, Hay J. Fine mapping and sequencing of a variable segment in the inverted repeat region of varicella-zoster virus DNA. J Virol. 1985;54(2):639-42. PubMed PMID: 2985828.

5. Ostrove JM, Reinhold W, Fan CM, Zorn S, Hay J, Straus SE. Transcription mapping of the varicella-zoster virus genome. J Virol. 1985;56(2):600-6. PubMed PMID: 2997479.

6. Reinhold W, Straus S, Ostrove J. Directionality and further mapping of varicella zoster virus transcripts. Virus Res. 1988;9(2-3):249-61. PubMed PMID: 2833048.

7. Schulte H, Oldfield E, Allolio B, Reinhold W, Ali I. Determination by X-chromosome inactivation analysis. Clinical Research 1990;38;2:341A.

8. Ali IU, Reinhold, W., Salvador, C., and Aguanno, S. Aberrent splicing of Gs- alpha transcript in transformed human astroglial and glioblastoma cell lines. Nucleic Acids Research Vol 20, No16:4263-4267. 1992.

9. Berkman RA, Merill, M.J., Reinhold, W.C., Monacci, W.T., Saxena, A., Clark, W.C., Robertson, J.T., Ali, I.U., and Oldfield, E.H. Expression of the vascular permiability factor/vascular endothelial growth factor gene in central nervous system neoplasms. The Journal of Clinical Investigation Vol 91:153-159. 1993.

10. Reinhold W, Ben-Barch N, Alexandrova N, Ichinose I, Blake M, Trepel J, et al. C-myc downregulation in suramin treated HL60 cells precedes growth inhibition but does not trigger differentiation. Molecular Pharmacology Vol 46, No 1:73-78. 1994.

11. Reinhold W, Emens L, Itkes A, Blake M, Ichinose I, Zajac-Kaye M. The myc intron-binding polypeptide associates with RFX1 in vivo and binds to the major histocompatibility complex class II promoter region, to the hepatitis B virus enhancer, and to regulatory regions of several distinct viral genes. Mol Cell Biol. 1995;15(6):3041-8. PubMed PMID: 7760800.

12. Bartosova Z, Pirsel M, Reinhold W, Stetler-Stevenson M, Zajac-Kaye M, May A, et al. Gene-specific repair in human CD4+ lymphocytes reflects transcription and proliferation. Mutat Res. 1996;363(3):191-9. PubMed PMID: 8765160.

13. Orr MS, Reinhold W, Yu L, Schreiber-Agus N, O'Connor PM. An important role for the retinoblastoma protein in staurosporine- induced G1 arrest in murine embryonic fibroblasts. J Biol Chem. 1998;273(7):3803-7. PubMed PMID: 9461560.

14. Fan S, Cherney B, Reinhold W, Rucker K, O'Connor PM. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment. Clinical cancer research : an official journal of the American Association for Cancer Research. 1998;4(4):1047-54. PubMed PMID: 9563901.

15. Russo P, Ottoboni C, Falugi C, Reinhold W, Riou JF, Parodi S, et al. Cellular effects of a new farnesyltransferase inhibitor, RPR-115135, in a human isogenic colon cancer cell line model system HCT-116. Ann N Y Acad Sci. 1999;886:252-6. Epub 2000/02/10. PubMed PMID: 10667232.

16. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet2000. p. 236-44.

17. Weinstein JN, Waltham M, Reinhold W, Lee JK, Smith LH, Andrews D, et al. The current revolution in cancer drug discovery: Genomics,

proteomics, and bioinformatics. . Proc Third Shizuoka Forum on Health

and Longevity. 2000;8-13.

18. Staunton JE, Slonim DK, Coller HA, Tamayo P, Angelo MJ, Park J, et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A2001. p. 10787-92.

19. Weinstein JN, Scherf U, Lee JK, Nishizuka S, Gwadry F, Bussey AK, et al. The bioinformatics of microarray gene expression profiling. Cytometry. 2002;47(1):46-9. PubMed PMID: 11774349.

20. Zhou Y, Gwadry, F.G., Reinhold, W.C., Miller, L., Smith, L.H., Scherf,, U. L, E., Kohn, K.W., Pommier, Y., and Weinstein, J.N. Transcriptional regulation of mitotic genes by camptothecin-induced DNA

damage: Microarray analysis of dose- and time-dependent effects. Cancer Research, 62, 1688-1695. 2002.

21. Rahman L, Bliskovski, V., Reinhold, W., and Zajac-Kaye, M. Alternative splicing of brain-specific PTB defines a tissue-specific isoform pattern that predicts distinct functional roles. Genomics. 2002.

22. Reinhold W, Kouros-Mehr H, Maunakea A, Kohn K, Lababidi S, Pantazis P, et al. Apoptotic response and the mechanism of resistance to camptothecin: a study of gene expression and functional effects. . European Journal of Cancer. 2002;38(7), S165, Nov. .

23. Reinhold WC, Kouros-Mehr H, Kohn KW, Maunakea AK, Lababidi S, Roschke A, et al. Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping. Cancer Res. 2003;63(5):1000-11. Epub 2003/03/05. PubMed PMID: 12615715.

24. Zeeberg B.R., Feng W., Wang G., Wang M.D., Fojo A.T., Sunshine M., et al. GoMiner: a resource for biological interpretation of genomic and proteomic data. . Genome Biol 2003;4(4):R28.

25. Daoud SS, Munson PJ, Reinhold W, Young L, Prabhu QY, LaRose J, et al. Impact of p53 knockout and topotecan treatment on gene expression profiles in himan colon carcinoma cells: a pharmacogenomic study. . Cancer Research. 2003;63, 2782-2793, June 1.

26. Bussey KJ, Kane D, Sunshine M, Narasimhan S, Nishizuka S, Reinhold WC, et al. MatchMiner: a tool for batch navigation among gene and gene product identifiers. . Genome Biol 2003;4(4):R27.

27. Nishizuka S, Chen ST, Gwadry FG, Alexander J, Major SM, Scherf U, et al. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res. 2003;Sep 1;63(17):5243-50.

28. Reinhold W.C., Kouros-Mehr H., Kohn K.W., Maunakea A.K., Lababidi S., Roschke A., et al. Permissive apoptosis-resistance (PAR): A two-step model for development of resistance to anticancer drugs. Frontiers in Science 2003;Vol. 3, 2-3, Sept. .

29. Nishizuka S, Charboneau L, Young L, Major S, Reinhold WC, Waltham M, et al. Proteomic profiling of the NCI60 cancer cell lines using new high-density ‘reverse-phase’ lysate microarrays. Proc Natl Acad Sci U S A. 2003;Nov 25;100(24):14229-34. Epub 2003 Nov 17.

30. Lee J, Scherf U, Staunton J, Slonim D, Bussey K, Ajay, et al. Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells. Genome Biol. 2003;4(12):R82. Epub 2003 Nov 25.

31. Feng W, Wang G, Zeeberg BR, Guo K, Fojo AT, Kane DW, et al. Development of gene ontology tool for biological interpretation of genomic and proteomic data. AMIA Annu Symp Proc. 2003;839.

32. Huang Y, Anderle P, Bussey KJ, Barbacioru C, Shankavaram U, Dai Z, et al. Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res. 2004;Jun 15;64(12):4294-301.

33. Szakacs G, Annereau J, Lababidi S, Shankavaram U, Arciello A, Bussey K, et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell. 2004;Aug;6(2):129-37.

34. Annereau JP, Szakacs G, Tucker CJ, Arciello A, Cardarelli C, Collins J, et al. Analysis of ABC transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance. Mol Pharmacol. 2004; Sep 1 [Epub ahead of print].

35. Bussey KJ, Chin K, Lababidi S, Reimers M, Reinhold WC, Kuo WL, et al. Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther. 2006;Apr;5(4):853-67.

36. Lorenzi PL, Reinhold WC, Rudelius M, Gunsior M., Shankavaram U, Kimberly J, et al. Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther. 2006;5(11).

37. Ikediobi ON, Davies H, Bignell G, Edkins S, Stevens C, O'meara S, et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther. 2006;Nov;5(11):2606-12.

38. Reinhold WC, Reimers MA, Maunakea AK, Kim S, Lababidi S, Scherf U, et al. Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells. Mol Cancer Ther. 2007;Feb;6(2):391-403.

39. Shankavaram UT, Reinhold WC, Nishizuka S, Major S, Morita D, Chary KK, et al. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther. 2007;Mar;6(3):820-32.

40. Blower PE, Verducci JS, Lin S ZJ, Chung JH, Dai Z, Liu CG, et al. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther. 2007;May;6(5):1483-91.

41. Liu H, Zeeberg BR, Qu G, Koru AG, Ferrucci A, Kahn A, et al. AffyProbeMiner: a web resource for computing or retrieving accurately redefined Affymetrix probe sets. Bioinformatics. 2007;Sep 15;23(18):2385-90.

42. Blower PE, Chung JH, Verducci JS, Lin S, Park JK, Dai Z, et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther. 2008.

43. Lorenzi PL, Llamas J, Gunsior M, Ozbun L, Reinhold WC, Varma S, et al. Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines. Mol Cancer Ther. 2008;Oct;7(10):3123-8.

44. Lorenzi P, Reinhold W, Varma S, Hutchinson A, Pommier Y, Chanock S, et al. DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther. 2009;8:713-24.

45. Pfister TD, Reinhold WC, Agama K, Gupta S, Khin SA, Kinders RJ, et al. Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity. Mol Cancer Ther. 2009;8(7):1878-84. Epub 2009/07/09. doi: 1535-7163.MCT-09-0016 [pii]

10.1158/1535-7163.MCT-09-0016. PubMed PMID: 19584232.

46. Shankavaram UT, Varma S, Kane D, Sunshine M, Chary KK, Reinhold WC, et al. CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics. 2009;10:277. Epub 2009/06/25. doi: 1471-2164-10-277 [pii]

10.1186/1471-2164-10-277. PubMed PMID: 19549304; PubMed Central PMCID: PMC2709662.

47. Choi W, Miyamura Y, Wolber R, Smuda C, Reinhold W, Liu H, et al. Regulation of Human Skin Pigmentation in situ by Repetitive UV Exposure: Molecular Characterization of Responses to UVA and/or UVB. J Invest Dermatol. 2010. Epub 2010/02/12. doi: jid20105 [pii]

10.1038/jid.2010.5. PubMed PMID: 20147966.

48. Liu H, Petula D’Andrade, Stephanie Fulmer-Smentek, Philip Lorenzi, Kurt W. Kohn, John N. Weinstein, et al. mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities. MCT. 2010;9(5):1080-1091.

49. Reinhold WC, Mergny JL, Liu H, Ryan M, Pfister TD, Kinders R, et al. Exon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron. Cancer Res. 2010;70(6):2191-203. Epub 2010/03/11. doi: 0008-5472.CAN-09-3528 [pii]

10.1158/0008-5472.CAN-09-3528. PubMed PMID: 20215517.

50. Reinhold WC, Reimers MA, Lorenzi P, Ho J, Shankavaram UT, Ziegler MS, et al. Multifactorial regulation of E-cadherin expression: an integrative study. Mol Cancer Ther. 2010;9(1):1-16. Epub 2010/01/08. doi: 1535-7163.MCT-09-0321 [pii]

10.1158/1535-7163.MCT-09-0321. PubMed PMID: 20053763; PubMed Central PMCID: PMC2821037.

51. Gmeiner WH, Reinhold WC, Pommier Y. Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons. Mol Cancer Ther. 2010;9(12):3105-14. Epub 2010/12/17. doi: 9/12/3105 [pii]

10.1158/1535-7163.MCT-10-0674. PubMed PMID: 21159603; PubMed Central PMCID: PMC3059097.

52. Chen CF, He X, Arslan AD, Mo YY, Reinhold WC, Pommier Y, et al. Novel regulation of nuclear factor-YB by miR-485-3p affects the expression of DNA topoisomerase IIalpha and drug responsiveness. Mol Pharmacol. 2011;79(4):735-41. Epub 2011/01/22. doi: mol.110.069633 [pii]

10.1124/mol.110.069633. PubMed PMID: 21252292; PubMed Central PMCID: PMC3063729.

53. Eddy J, Vallur AC, Varma S, Liu H, Reinhold WC, Pommier Y, et al. G4 motifs correlate with promoter-proximal transcriptional pausing in human genes. Nucleic Acids Res. 2011;39(12):4975-83. Epub 2011/03/05. doi: gkr079 [pii]

10.1093/nar/gkr079. PubMed PMID: 21371997; PubMed Central PMCID: PMC3130262.

54. Zeeberg BR, Liu H, Kahn AB, Ehler M, Rajapakse VN, Bonner RF, et al. RedundancyMiner: De-replication of redundant GO categories in microarray and proteomics analysis. BMC Bioinformatics. 2011;12:52. Epub 2011/02/12. doi: 1471-2105-12-52 [pii]

10.1186/1471-2105-12-52. PubMed PMID: 21310028.

55. Martin MM, Ryan M, Kim R, Zakas AL, Fu H, Lin CM, et al. Genome-wide depletion of replication initiation events in highly transcribed regions. Genome Res. 2011. Epub 2011/08/05. doi: gr.124644.111 [pii]

10.1101/gr.124644.111. PubMed PMID: 21813623.

56. Zoppoli G, Solier S, Reinhold WC, Liu H, Connelly JW, Jr., Monks A, et al. CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute. Oncogene. 2011. Epub 2011/07/19. doi: onc2011283 [pii]

10.1038/onc.2011.283. PubMed PMID: 21765476.

57. Zoppoli G, Douarre C, Dalla Rosa I, Liu H, Reinhold W, Pommier Y. Coordinated regulation of mitochondrial topoisomerase IB with mitochondrial nuclear encoded genes and MYC. Nucleic Acids Res. 2011;39(15):6620-32. Epub 2011/05/03. doi: 10.1093/nar/gkr208. PubMed PMID: 21531700; PubMed Central PMCID: PMC3159436.

58. Reinhold WC, Erliandri I, Liu H, Zoppoli G, Pommier Y, Larionov V. Identification of a predominant co-regulation among kinetochore genes, prospective regulatory elements, and association with genomic instability. PLoS One. 2011;6(10):e25991. Epub 2011/10/22. doi: 10.1371/journal.pone.0025991

PONE-D-11-09581 [pii]. PubMed PMID: 22016797; PubMed Central PMCID: PMC3189923.

59. Zeeberg BR, Reinhold W, Snajder R, Thallinger GG, Weinstein JN, Kohn KW, et al. Functional Categories Associated with Clusters of Genes That Are Co-Expressed across the NCI-60 Cancer Cell Lines. PLoS One. 2012;7(1):e30317. Epub 2012/02/01. doi: 10.1371/journal.pone.0030317

PONE-D-11-11112 [pii]. PubMed PMID: 22291933; PubMed Central PMCID: PMC3265467.

60. Ruan X, Kocher JP, Pommier Y, Liu H, Reinhold WC. Mass Homozygotes Accumulation in the NCI-60 Cancer Cell Lines As Compared to HapMap Trios, and Relation to Fragile Site Location. PLoS One. 2012;7(2):e31628. Epub 2012/02/22. doi: 10.1371/journal.pone.0031628

PONE-D-11-09941 [pii]. PubMed PMID: 22347499; PubMed Central PMCID: PMC3276511.

61. Cunningham L, Finckbeiner S, Hyde RK, Southall N, Marugan J, Yedavalli VR, et al. Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFbeta interaction. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(36):14592-7. Epub 2012/08/23. doi: 10.1073/pnas.1200037109. PubMed PMID: 22912405.

62. Kohn KW, Zeeberg BR, Reinhold WC, Sunshine M, Luna A, Pommier Y. Gene expression profiles of the NCI-60 human tumor cell lines define molecular interaction networks governing cell migration processes. PLoS One. 2012;7(5):e35716. Epub 2012/05/10. doi: 10.1371/journal.pone.0035716. PubMed PMID: 22570691; PubMed Central PMCID: PMC3343048.

63. Kouprina N, Lee NC, Pavlicek A, Samoshkin A, Kim JH, Lee HS, et al. Exclusion of the 750-kb genetically unstable region at Xq27 as a candidate locus for prostate malignancy in HPCX1-linked families. Genes Chromosomes Cancer. 2012;51(10):933-48. Epub 2012/06/27. doi: 10.1002/gcc.21977. PubMed PMID: 22733720; PubMed Central PMCID: PMC3412920.

64. Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J, et al. CellMiner: A Web-Based Suite of Genomic and Pharmacologic Tools to Explore Transcript and Drug Patterns in the NCI-60 Cell Line Set. Cancer Res. 2012;(72):13. Epub July 15. doi: 10.1158/0008-5472.

65. Schowalter RM, Reinhold WC, Buck CB. Entry Tropism of BK and Merkel Cell Polyomaviruses in Cell Culture. PLoS One. 2012;7(7):e42181. Epub 2012/08/04. doi: 10.1371/journal.pone.0042181. PubMed PMID: 22860078; PubMed Central PMCID: PMC3409148.

66. Zeeberg BR, Kohn KW, Kahn A, Larionov V, Weinstein JN, Reinhold W, et al. Concordance of Gene Expression and Functional Correlation Patterns across the NCI-60 Cell Lines and the Cancer Genome Atlas Glioblastoma Samples. PLoS One. 2012;7(7):e40062. Epub 2012/08/01. doi: 10.1371/journal.pone.0040062. PubMed PMID: 22848369; PubMed Central PMCID: PMC3406063.

67. Zoppoli G, Regairaz M, Leo E, Reinhold WC, Varma S, Ballestrero A, et al. Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(37):15030-5. Epub 2012/08/29. doi: 10.1073/pnas.1205943109. PubMed PMID: 22927417.

68. Giovinazzi S, Morozov VM, Summers MK, Reinhold WC, Ishov AM. USP7 and Daxx regulate mitosis progression and taxane sensitivity by affecting stability of Aurora-A kinase. Cell Death Differ. 2013. Epub 2013/01/26. doi: 10.1038/cdd.2012.169. PubMed PMID: 23348568.

69. Jung H, Wang H, Patel R, Phillips B, Reinhold W, Cohen D, et al. miR-375 regulation of CIP2A controls oral cancer cell proliferation and survival. Molecular Biology of the Cell. 2013.

70. Abaan OD, Poley EC, Davis SR, Zhu YJ, Bilke S, Walker RL, et al. The Exomes of the NCI-60 Panel: A Genomic Resource for 3 Cancer Biology and Systems Pharmacology. Cancer Research. 2013.

71. Reinhold W. Commentary on “MelanomaDB: a Web Tool for Integrative Analysis of Melanoma Genomic Information to Identify Disease-Associated Molecular Pathways. Frontiers in Cancer Genetics. 2013;(1664-8021).

72. Kohn KW, Zeeberg BM, Reinhold WC, Pommier Y. Gene expression correlations in human cancer cell lines define molecular interaction networks for epithelial phenotype. PLoS One. 2014;9(6):e99269. doi: 10.1371/journal.pone.0099269. PubMed PMID: 24940735; PubMed Central PMCID: PMC4062414.

73. Giovinazzi S, Sirleto P, Aksenova V, Morozov VM, Zori R, Reinhold WC, et al. Usp7 protects genomic stability by regulating Bub3. Oncotarget. 2014;5(11):3728-42. PubMed PMID: 25003721.

74. Varma S, Pommier Y, Sunshine M, Weinstein JN, Reinhold WC. High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner. PLoS One. 2014;9(3):e92047. doi: 10.1371/journal.pone.0092047. PubMed PMID: 24670534; PubMed Central PMCID: PMC3966786.

75. Reinhold WC, Varma S, Sousa F, Sunshine M, Abaan OD, Davis SR, et al. NCI-60 Whole Exome Sequencing and Pharmacological CellMiner Analyses. PLoS One. 2014;9(7):e101670. doi: 10.1371/journal.pone.0101670. PubMed PMID: 25032700.

76. Reinhold WC, Varma S, Rajapakse VN, Luna A, Sousa FG, Kohn KW, et al. Using drug response data to identify molecular effectors, and molecular "omic" data to identify candidate drugs in cancer. Human genetics. 2015;134(1):3-11. doi: 10.1007/s00439-014-1482-9. PubMed PMID: 25213708.

77. Tsuji PA, Carlson BA, Yoo MH, Naranjo-Suarez S, Xu XM, He Y, et al. The 15kDa Selenoprotein and Thioredoxin Reductase 1 Promote Colon Cancer by Different Pathways. PLoS One. 2015;10(4):e0124487. doi: 10.1371/journal.pone.0124487. PubMed PMID: 25886253; PubMed Central PMCID: PMC4401539.

78. Sousa FG, Matuo R, Tang SW, Rajapakse VN, Luna A, Sander C, et al. Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity. DNA repair. 2015;28:107-15. doi: 10.1016/j.dnarep.2015.01.011. PubMed PMID: 25758781; PubMed Central PMCID: PMC4385398.

79. Reinhold WC, Sunshine M, Varma S, Doroshow JH, Pommier Y. Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015;21(17):3841-52. doi: 10.1158/1078-0432.CCR-15-0335. PubMed PMID: 26048278; PubMed Central PMCID: PMC4558215.

80. Nogales V, Reinhold WC, Varma S, Martinez-Cardus A, Moutinho C, Moran S, et al. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs. Oncotarget. 2015. doi: 10.18632/oncotarget.6413. PubMed PMID: 26625211.

81. Luna A, Rajapakse VN, Sousa FG, Gao J, Schultz N, Varma S, et al. rcellminer: exploring molecular profiles and drug response of the NCI-60 cell lines in R. Bioinformatics. 2015. doi: 10.1093/bioinformatics/btv701. PubMed PMID: 26635141.

82. Reinhold WC. Current dichotomy between traditional molecular biological and omic research in cancer biology and pharmacology. World Journal of Clinical Oncology. 2015;6(6). Epub Dec. 10, 2015. doi: http://dx.doi.org/10.5306/wjco.v6.i6.184.

83. Robert J, Reinhold WC. [Bisphosphonates as new anticancer agents?]. Bulletin du cancer. 2015;102(4):297-9. doi: 10.1016/j.bulcan.2015.02.010. PubMed PMID: 26042254.

84. Nogales V, Reinhold WC, Varma S, Martinez-Cardus A, Moutinho C, Moran S, et al. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs. Oncotarget. 2016;7(3):3084-97. doi: 10.18632/oncotarget.6413. PubMed PMID: 26625211.